Skip to main content

Table 1 Demographic, clinical, and laboratory characteristics of the studied AML patients

From: Reductive regulation of BECN1 gene in adult Egyptian patients with do novo AML

Parameter AML patients (total no. = 50)
Sex [n (%)]
 Females 28 (56.0%)
 Males 22 (44.0%)
Age (years)
 Mean ± SD (51.56 ± 20.17)
Clinical data [n (%)]
 Fever 11(22.0%)
 Hepatomegaly 19(38.0%)
 Splenomegaly 19(38.0%)
 Lymphadenopathy 4(8.0%)
TLC (x109/L) (Median—IQR) 54.8 (22.3–76.4)
Hb (g/dl) (Mean ± SD) (8.09 ± 2.01)
PLT (x109/L) (Median—IQR) 33 (24–68)
PB blasts (%) (Mean ± SD) (56.96 ± 23.43)
BM blasts (%) (Mean ± SD) (75.68 ± 20.83)
Immunophenotyping [n (%)]
 CD34 + 33 (66.0%)
 CD117 + 32 (64.0%)
 HLA-DR + 43 (86.0%)
FAB subtypes [n (%)]
 M0 5 (10.0%)
 M1 10 (20.0%)
 M2 20 (40.0%)
 M3 5 (10.0%)
 M4 7 (14.0%)
 M5 3(6.0%)
Molecular abnormalities [n (%)]
 Wild type NPM1 5 (10.0%)
 Mutated NPM1 and FLT3-ITD 2 (4.0%)
 FLT3-ITD mutation 14 (28.0%)
 c-KIT mutation 8 (16.0%)
Cytogenetic risk groups [n (%)]
 Favourable 11 (22.0%)
 Intermediate 10 (20.0%)
 Adverse 29 (58.0%)
Response to induction therapy (D28) [n (%)]
 Responders 15 (30.0%)
 Non- responders 35 (70.0%)
  1. TLC total leukocytic count, Hb haemoglobin, PLT platelets, BM bone marrow, PB peripheral blood, FAB French American British, SD standard deviation, IQR interquartile range, NPM1 Nucleophosmin, ITD internal tandem duplication